$NVLX contractor, Inno Biologics Sdn. Bhd., is u

$NVLX contractor, Inno Biologics Sdn. Bhd., is using the Clone-Pix ™ technology for the isolation and selection of clones preparatory to obtaining the large numbers of cells for Nuvilex's future clinical trials in advanced, inoperable pancreatic cancer.

Clone-Pix ™ is considered to be "state-of–the-art" technology in the cloning process. It is an instrument that allows for the automated isolation of high value clones of mammalian cells. Clone-Pix ™ is now employed by more than 100 laboratories and entities throughout the world and is used by notable pharmaceutical and biotech companies such as Merck, GlaxoSmithKline, Wyeth and Genentech. By employing this technology, workflow throughout the cloning process is increased and this allows for more clones to be screened in less time than would be possible using conventional technologies.

Clone-Pix ™ allows for the gentle "picking" of clones to ensure high viability of the selected clones. The "best clones" for Nuvilex's purposes will be isolated, tested and propagated to obtain the requisite numbers of cells for cellulose-based encapsulation that will ultimately form part of Nuvilex's treatment for advanced pancreatic cancer. The most desirable of the selected clones will be those that have elevated activity of the enzyme that converts the cancer prodrug ifosfamide into its cancer-killing form.

Nuvilex's Chief Scientific Officer, Dr. Robert F. Ryan commented, "Through the use of Clone-Pix ™ , Inno Biologics will be able to optimize the selection of the most desirable clones for Nuvilex to use in producing adequate numbers of cells for our future late-phase clinical trials as expeditiously as possible. The availability of the Clone-Pix ™ technology at Inno Biologics was a significant factor in our choosing that company to conduct this very important phase of our preparations for those trials." http://www.stockwatch.com/News/Item.aspx?bid=...p;region=U